TuisATHA • NASDAQ
add
Athira Pharma Inc
Vorige sluiting
$0,66
Dagwisseling
$0,63 - $0,66
Jaarwisseling
$0,41 - $4,30
Markkapitalisasie
24,64 m USD
Gemiddelde volume
9,62 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 25,49 m | -27,25% |
Netto inkomste | -28,74 m | 12,83% |
Netto winsgrens | — | — |
Wins per aandeel | — | — |
EBITDA | -25,25 m | 27,44% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 68,86 m | -60,19% |
Totale bates | 86,25 m | -53,30% |
Totale aanspreeklikheid | 28,66 m | -4,25% |
Totale ekwiteit | 57,58 m | — |
Uitstaande aandele | 38,67 m | — |
Prys om te bespreek | 0,44 | — |
Opbrengs op bates | -64,54% | — |
Opbrengs op kapitaal | -88,74% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -28,74 m | 12,83% |
Kontant van bedrywe | -23,02 m | 4,01% |
Kontant van beleggings | 18,04 m | -12,81% |
Kontant van finansiering | 12,00 k | — |
Netto kontantverandering | -4,97 m | -50,94% |
Beskikbare kontantvloei | -10,13 m | 13,86% |
Meer oor
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Gestig
2011
Hoofkwartier
Webwerf
Werknemers
66
